Alcon, Inc. (ACL) Completes Acquisition of DUREZOL(TM) and ZYCLORIN(TM) from Sirion Therapeutics  
3/30/2010 8:50:16 AM

HUENENBERG, Switzerland--(BUSINESS WIRE)--Alcon (NYSE:ACL), the world’s leader in eye care, announced today that it received regulatory approval and finalized the acquisition of the rights in the United States for DUREZOL™ emulsion and the global rights, excluding Latin America, for ZYCLORIN™ from Sirion Therapeutics, Inc. Alcon will immediately assume all marketing, promotion and sales of DUREZOL™. Management said that it is continuing to evaluate options to acquire ZIRGAN™, an antiviral recently approved by the FDA for the treatment of acute herpetic keratitis (corneal ulcers).